Adult: As norethisterone enantate: 200 mg given within the first 5 days of menstrual cycle (counting the 1st day as day 1) or immediately after giving birth, may repeat dose every 8 weeks.
Oral Postponement of menstruation
Adult: 5 mg tid for up to 14 days, starting 3 days before expected onset of menstruation.
Oral Dysfunctional uterine bleeding
Adult: 5 mg tid for 10 days. For prevention of recurrence: 5 mg bid from the 19th-26th day of the 2 subsequent cycles. As norethisterone acetate: 2.5-10 mg daily for 5-10 days.
Adult: 5 mg bid-tid from the 19th-26th day of cycle (count the 1st day of menstruation as day 1).
Adult: 10-20 mg daily starting between 1st and 5th day of the cycle, continuously for 4-6 months or longer. As norethisterone acetate: 5-15 mg daily; start at 5 mg daily and increase by 2.5 mg at 14-day intervals; take continuously for 6-9 months.
Oral Premenstrual syndrome
Adult: 5 mg bid-tid on days 19th-26th day of the cycle. May repeat treatment for several cycles.
Adult: 0.35 mg daily, starting on the 1st day of menstruation, or on the day after abortion or miscarriage, or on the 21st day after childbirth. Take continuously as long as contraception is desired.
Adult: 5 mg tid for 20 days, starting on the 5th day of the cycle (count the 1st day of menstruation as day 1). Maintain treatment for 3-4 cycles followed by treatment-free cycles.
May be taken with or without food.
Known, suspected, or history of breast cancer or endometrial cancer, active or recent arterial thromboembolic disease (e.g. stroke, MI), current or history of venous thromboembolism (e.g. DVT, pulmonary embolism), angina pectoris, undiagnosed vaginal bleeding, porphyria, benign or malignant hepatic tumour; severe diabetes with vascular changes, pathologically increased blood pressure (as norethisterone enantate). Hepatic impairment or disease (e.g. Dubin-Johnson syndrome, Rotor syndrome). Pregnancy.
Patient with risk factors for cardiovascular disease (e.g. hypercholesterolaemia, hypertension, obesity), and/or venous thromboembolism (e.g. personal or family history of venous thromboembolism, SLE, prolonged immobilisation); depression, diabetes mellitus, conditions that may be aggravated by fluid retention (e.g. asthma, migraine, epilepsy, cardiac dysfunction). Smokers. Renal impairment. Lactation.
Significant: Irregular menstrual bleeding, breast cancer, visual abnormalities (e.g. partial or complete loss of vision, proptosis, diplopia), migraine, depression, decreased glucose tolerance, venous thromboembolism (e.g. deep vein thrombosis). Rarely, benign or malignant liver tumour. Gastrointestinal disorders: Nausea, vomiting, abdominal pain. General disorders and administration site conditions: Fatigue. Hepatobiliary disorders: Cholestatic jaundice. Immune system disorders: Hypersensitivity. Investigations: Weight gain, abnormal LFT. Metabolism and nutrition disorders: Oedema. Nervous system disorders: Headache, dizziness. Psychiatric disorders: Insomnia. Reproductive system and breast disorders: Breast tenderness, amenorrhoea, spotting, decreased libido, change in cervical secretions, cervical erosion, breast hypertrophy. Skin and subcutaneous tissue disorders: Acne, chloasma, pruritus, urticaria.
Assess pregnancy status prior to therapy, diagnostic measures (e.g. endometrial sampling). Monitor weight, vision changes (e.g. loss of vision, diplopia), signs or symptoms of depression, glycaemic control (in diabetic patients), lipid profile (patients treated for hyperlipidaemia). Perform breast and pelvic examination (e.g. Papanicolaou smear), as necessary.
Symptoms: Nausea, vomiting, breast enlargement, vaginal bleeding. Management: Symptomatic treatment. May employ gastric lavage within 4 hours of ingestion in case of large overdose.
Decreased therapeutic effect with barbiturates, phenytoin, carbamazepine, griseofulvin, felbamate. Increased plasma concentrations with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, verapamil, diltiazem). May reduce the therapeutic effect of ulipristal.
Diminished therapeutic effect with St. John’s wort.
May interfere with tests for binding proteins (e.g. thyroid-binding globulin), glucose metabolism, coagulation, and LFT. May reduce the response to metyrapone test.
Description: Norethisterone has typical effects of a progestogen and converts the endometrium from the proliferative to the secretory phase. It inhibits the secretion of the pituitary gonadotropins thus preventing follicular maturation and ovulation. In addition, it increases the cervical mucous viscosity and alters the endometrium resulting to impaired implantation and blocked sperm penetration, respectively.
Synonym: Norethindrone. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: 64%. Time to peak plasma concentration: Approx 1-2 hours. Distribution: Enters breastmilk. Volume of distribution: 4 L/kg. Plasma protein binding: Approx 60% to albumin; 35% to sex hormone binding globulin. Metabolism: Undergoes extensive hepatic first-pass effect Norethisterone acetate is deacetylated to norethisterone which further undergoes hepatic reduction and conjugation. Norethisterone is also metabolised to ethinylestradiol. Excretion: Via urine (>50%, as metabolites); faeces (20-40%, as metabolites). Elimination half-life: Approx 8-9 hours.
G03DC02 - norethisterone ; Belongs to the class of estren derivative progestogens used in progestogenic hormone preparations. G03AC01 - norethisterone ; Belongs to the class of progestogens. Used as systemic contraceptives.
Anon. Norethindrone Acetate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 09/12/2019.Anon. Norethindrone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/12/2019.Buckingham R (ed). Norethisterone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/12/2019.Joint Formulary Committee. Norethisterone. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/12/2019.Norethindrone 0.35 mg Tablet (Lupin Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 29/01/2020.Norethindrone Acetate Tablet (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/12/2019.Norethindrone. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 09/12/2019.